Abstracts tagged "obesity"

Abstract Number: 1011 • ACR Convergence 2025
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Ethan Eickmann¹, Daniel Betensky¹, Karen Smith¹, Candace Feldman¹, Jason Kim², Ankur Pandya³, Jeffrey Katz⁴ and Elena Losina⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Arthritis Foundation, Atlanta, GA, ³Harvard School of Public Health, Boston, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵BWH, Boston, MA
Background/Purpose: US federal law currently does not allow Medicare Part D coverage for weight loss medications without additional indications, such as diabetes. Several glucagon-like peptide-1…
Abstract Number: 0813 • ACR Convergence 2025
Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study
Gregory Challener¹, Kevin Sheng-Kai Ma², Natalie McCormick³, Minna Kohler⁴, Janeth Yinh³, Chio Yokose⁵, Sharan Rai⁶, Florence Porterfield⁷, Fatima Stanford⁸, Dong Wook Kim⁹, April Jorge³ and Hyon K. Choi¹⁰, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Waltham, MA, ⁶Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁷Division of Endocrinology, Massachusetts General Hospital, Boston, ⁸Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁹Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ¹⁰MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Tirzepatide is a dual GIP/GLP-1 receptor co-agonist approved for weight loss in patients with obesity or body mass index (BMI) > 27 kg/m2 with…
Abstract Number: 0438 • ACR Convergence 2025
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
Bindee Kuriya¹, Susan J. Bartlett², Marie-France Valois³, Janet Pope⁴, Carter Thorne⁵, Carol Hitchon⁶, Hugues Allard-Chamard⁷, Glen Hazlewood⁸, Gilles Boire⁹, Louis Bessette¹⁰ and Vivian Bykerk¹¹, ¹Mount Sinai Health, Toronto, Canada, ²McGill University, Beaconsfield, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Centre of Arthritis Excellence, Newmarket, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Retired, Sherbrooke, QC, Canada, ¹⁰Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
Abstract Number: 2660 • ACR Convergence 2025
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Shreya Billa¹, Sho Fukui¹, Misti Paudel², Takahiro Suzuki³, Ryosuke Imai⁴, Yuntae Kim⁵, Takehiro Nakai⁶, Hiromichi Tamaki⁶, mitsumasa kishimoto⁷, Hilde Ørbo¹, Sara Tedeschi¹, Hyon K. Choi⁸, Masato Okada⁹ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Department of Cardiovascular Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁷Kyorin University School of Medicine, Tokyo, Japan, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout,…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…
Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Joshua Baker¹, George Reed², Geoffrey Thiele³, Dimitrios Pappas⁴, christina Charles-Schoeman⁵, Monica Guma⁶, Leslie Harrold⁷, Jeffrey Curtis⁸ and Joel Kremer⁹, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴CorEvitas, New York, NY, ⁵UCLA Medical Center, Santa Monica, CA, ⁶UCSD, La Jolla, CA, ⁷CorEvitas, Northborough, MA, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Michael Nevitt⁴, C.E. Lewis⁵, James Torner⁶ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴UCSF, Orinda, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…
Abstract Number: 1050 • ACR Convergence 2024
The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity
Daniel Betensky¹, Jeffrey Katz¹, Catherine Yang², David Hunter³, Jamie Collins¹, Candace Feldman¹, Karen Smith¹, Stephen Messier⁴, Jason Kim⁵, Faith Selzer⁶ and Elena Losina¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁴Wake Forest University, Winston Salem, NC, ⁵Arthritis Foundation, Atlanta, GA, ⁶Brigham and Women's Hospital, Amesbury, MA
Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
Abstract Number: 1187 • ACR Convergence 2024
Association of Depressive Symptoms and Multiple Joint Osteoarthritis with Pain Outcomes in the WE-CAN Trial
Natalie Allcott¹, Stephen Messier², Shannon Mihalko², Jeffrey Katz³, Paul DeVita⁴, David Hunter⁵, Sara Quandt⁶, Carolina Alvarez⁷, Leigh Callahan⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Wake Forest University, Winston Salem, NC, ³Brigham and Women's Hospital, Brookline, MA, ⁴Eastern Carolina University, Greenville, ⁵Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁶Wake Forest University, Winston-Salem, ⁷University of North Carolina at Chapel Hill, Miami, FL, ⁸University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: The Weight-loss and Exercise for Communities with Arthritis in North Carolina (WE-CAN) trial was a community-based, pragmatic randomized clinical trial in men and women…
Abstract Number: 1192 • ACR Convergence 2024
Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Douglas Kiel⁴, Michael Nevitt⁵, C.E. Lewis⁶, James Torner⁷ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Hebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵UCSF, Orinda, CA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Iowa, Iowa City
Background/Purpose: Obesity [defined by body mass index (BMI) ≥30 kg/m2] is an established risk factor for incident radiographic knee OA (ROA). However, the relative contributions…
Abstract Number: 1379 • ACR Convergence 2024
Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis
Dong-Jin Park¹, Hyemin Jeong², Sung-Eun Choi³, Ji-Hyoun Kang² and Shin-Seok Lee⁴, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Recent studies have shown the impact of obesity on achieving low disease activity (LDA) or remission in rheumatoid arthritis (RA) patients treated with TNF…
Abstract Number: 1484 • ACR Convergence 2024
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Philip Carlucci¹, Brooke Cohen², Amit Saxena³, H Michael Belmont³, Mala Masson⁴, Heather Gold⁵, Jill Buyon² and Peter Izmirly⁶, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵NYU Langone Health, NYC, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications that significantly improve cardiometabolic outcomes. Whether these drugs may be useful in mitigating…
Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Rutvin Kyada¹, Jean Liew², Maureen Dubreuil³, Matthew Brown⁴, Mariko Ishimori⁵, John Reveille⁶, Michael Ward⁷, Michael Weisman⁸ and Lianne S Gensler⁹, ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁴King's College London, London, United Kingdom, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston, ⁷NIH, Bethesda, MD, ⁸Stanford University, Los Angeles, CA, ⁹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].